Suppl Fig S3 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer

Read full text Summarise with VIRAT
Authors: Florian Renner, Jan Eckmann, Cornelia Handl, Jürgen Wichmann, Gabriel Schnetzler, Nicole A. Kratochwil, Nino Keshelava, Javier Ros, Elena Élez, Jordi Vergés, Irene Chicote, Jordi Martínez‐Quintanilla
+2 more Héctor G. Pálmer, Piergiorgio Pettazzoni
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Western blot showing additive effect of combined inhibition of EGFR and MAPK signaling

Fields of Study & Subjects

Colorectal Cancer Treatments and Studies Melanoma and MAPK Pathways Lung Cancer Treatments and Mutations

Publication details

Publication date
2 April 2026
Language
EN